Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Gothenburg, September 13, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that ESGCT (European Society of Gene & Cell Therapy) and PEGS Europe (Protein & Antibody Engineering Summit) has selected the company's submitted abstracts entitled "Expression of a pathogenic virulence factor enhances the efficacy of CAR T-cell therapy against solid tumors" for oral presentations.

Elicera's Chief Development Officer, Dr Di Yu, will orally present preclinical proof-of-concept data for the company's iTANK platform during the upcoming ESGCT Collaborative Virtual Congress to be held on October 19-22, 2021. This is also the first time the iTANK platform will be publicly presented. Elicera's Chief Scientific Officer, professor Magnus Essand, will then present corresponding data and additional preclinical data on the company's CAR T-cell therapy for the treatment of B-cell lymphoma at PEGS Europe on November 2-4, 2021.

"The iTANK platform has been developed to improve the function of CAR T cells but also to activate a separate attack by the immune system against the entire set of relevant targets on cancer cells via the patient's own so-called killer T-cells," says CEO Jamal El-Mosleh. "We use the technology to strengthen our own drug candidates, including next generation of oncolytic viruses, which is why it is considered one of our most important assets. The platform however can be applied to all CAR T-cells under development and since they can meet two of the biggest challenges for CAR T-cells in the treatment of solid tumors, the area with the greatest potential, we see the platform itself as a very important business opportunity. That is why we are particularly looking forward to presenting the iTANK platform to various stakeholders publicly for the first time".

Source: Cision

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.